Polyrizon Completes Enrollment of 120 Patients in U.S. Clinical Study
Polyrizon says enrollment is complete for all 120 patients in a U.S. clinical study of its Nasarix allergy blocker.
Polyrizon says enrollment is complete for all 120 patients in a U.S. clinical study of its Nasarix allergy blocker.